Evidence map›Paper›PMID 42755684›Full record

ArticleFrontiers in systems biology2026

Innate immune activation profiles are associated with polarization of the T cell response to recombinant arenaviral vectors.

Sarah Szaffich, Valentin Just, Natalija Cvetkovic, Naila Pepic, Michael Schwendinger, Kia Katchar, Klaus K Orlinger, Henning Lauterbach, Josipa Raguz, Katell Bidet Huang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in systems biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sarah SzaffichHookipa Pharma Inc., New York, NY, United States.
Valentin JustHookipa Pharma Inc., New York, NY, United States.
Natalija CvetkovicHookipa Pharma Inc., New York, NY, United States.
Naila PepicHookipa Pharma Inc., New York, NY, United States.
Michael SchwendingerHookipa Pharma Inc., New York, NY, United States.
Kia KatcharHookipa Pharma Inc., New York, NY, United States.
Klaus K OrlingerHookipa Pharma Inc., New York, NY, United States.
Henning LauterbachHookipa Pharma Inc., New York, NY, United States.
Josipa RaguzHookipa Pharma Inc., New York, NY, United States.
Katell Bidet HuangHookipa Pharma Inc., New York, NY, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Arenavirus-based vectors are uniquely positioned to generate durable T cell responses against tumors, which remains a central challenge in cancer immunotherapy. Two members of the arenavirus family, Lymphocytic choriomeningitis virus and Pichinde virus, were genetically engineered to encode a non-oncogenic fusion protein, originating from human papillomavirus 16 E

Indexed as

immune responseimmunotherapyin vitro modelsingle-cell transcriptomicsviral vector

Identifiers

PMID42755684
PMCPMC13581738

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.